Literature DB >> 30844010

[Leprosy and primary care: an evaluation study from a medical perspective].

Gutembergue S de Sousa1, Rodrigo L Ferreira da Silva2, Marília Brasil-Xavier3.   

Abstract

OBJECTIVE: To assess the presence and extent of essential attributes derived from primary health care in a leprosy control program.
MATERIALS AND METHODS: This is an assessment of health programs, focused on leprosy and targeted at doctors working on control actions in a leprosy program of primary health care units. A questionnaire developed and validated in another study was used to measure the presence and scope of primary health care attributes in disease control. Data were entered into a database and statistical and descriptive analysis was carried out. This study was approved within the framework of CEP No. 1.128.385.
RESULTS: Overall scores and essential attributes of leprosy control actions showed a high exposure to leprosy control actions in the studied city. Community's access, orientation and guidance attributes averaged below the cutoff point, demonstrating the existing weaknesses in the items that make up these attributes.
CONCLUSION: Despite the weaknesses identified, the study showed high orientation towards the development of leprosy control actions, according to the assessment made by doctors working in primary care.

Entities:  

Mesh:

Year:  2018        PMID: 30844010     DOI: 10.15446/rsap.V20n3.56109

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  1 in total

1.  The interference of polypharmacy and the importance of clinical pharmacy advice in the treatment of leprosy: a case-control study.

Authors:  Selma Regina Penha Silva Cerqueira; Lais Sevilha Dos Santos; Elaine Faria Morelo; Agenor de Castro Moreira Dos Santos Júnior; Carlos Augusto Felipe de Sousa; Renata Trindade Gonçalves; Gunter Hans Neto; Daniel da Silva Marques; Raimunda Nonata Ribeiro Sampaio; Patrícia Shu Kurizky; Ciro Martins Gomes
Journal:  Rev Soc Bras Med Trop       Date:  2020-06-01       Impact factor: 1.581

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.